Design for Medical 3D Printing (Premium)

Design plays a pivotal role in the realm of 3D-printed medical devices, serving as a linchpin in ensuring safety, efficacy, and innovation. The unique capabilities of 3D printing technology allow for the creation of highly customized and intricate medical devices, tailored to the specific needs of individual patients or medical applications. An effective design process ensures that these devices not only meet their intended functions but also adhere to critical standards of biocompatibility, sterilization, and regulatory compliance. Precise design optimization can significantly reduce material waste, production time, and costs while enhancing the overall performance of these devices, making them more accessible and affordable to a wider range of patients and healthcare providers. Moreover, design innovation in 3D-printed medical devices can address unmet medical needs and improve patient outcomes. Customization is a hallmark of 3D printing, allowing for patient-specific implants, prosthetics, and anatomical models for surgical planning. Furthermore, the technology enables the integration of complex features such as lattice structures, drug delivery systems, and biomimetic designs that were previously unattainable through traditional manufacturing methods. In research and development, 3D printing facilitates rapid prototyping, enabling iterative testing and refinement, ultimately leading to breakthroughs in medical device functionality and performance. Thus, an emphasis on thoughtful and creative design in 3D printing for medical devices is paramount in advancing the healthcare industry, improving patient care, and driving innovation in the field. In this upcoming virtual event, 3DHEALS invites you to join a panel of design experts and startup founders to explore the future of DfAM (Design for Additive Manufacturing).


Nicholas Jacobson

Nicholas Jacobson

Nicholas Jacobson is trained as both an architect and a computational designer. He has a particular interest in a technically synthetic and logically rigorous approach to form and fabrication. As a practiced architect and designer, he has designed buildings for the aerospace industry, concert halls, ultra-high-end residential, operating rooms, and structures in extreme environments. Currently, he researches and develops novel methods and tools for complex surgeries leveraging disparate computational methods from numerous fields including Architecture, Animation, Fashion, Regenerative Medicine, and Structural Engineering. This work focuses on three areas of patient-specific focused development: Diagnostics, Prosthetics, and Implants. His work and research have been published in books, scholarly journals, magazines, and newspapers; these include: ACADIA, AD, CAADRIA, Code LA, Huffington Post, Modern Luxury, Nature, New York Times, Popular Science, Sky News, and Vogue and shown work both nationally and internationally. He has lectured at Harvard University, Stanford University, University of North Carolina, and the University of Denver and for companies such as AutoDesk, Zaha Hadid Architects, Medtronic, Edwards Lifesciences, Thornton Tomasetti, Stratasys, Trimble, and the Keynote speaker for AMUG 2023. He received a Bachelor’s in Architecture (Summa Cum Laude) from the University of Wisconsin SARUP and an M.Des (Design Technology) from Harvard GSD and the Harvard Business School.

Gokce (Gilly) Yildirim

Gilly is a biomedical engineer, inventor, and an operations leader with 20 years of medical device industry and scientific research experience, and currently is the founder and CEO of Vent Creativity Corporation, an AI based digital twin surgical planning and decision-making software serving the orthopaedics and healthcare community. Gilly started his career in industrial robotic automation, and then translated this knowledge to human biomechanics, design, testing, and regulatory filing of medical devices. Gilly previously advised a multi-billion-dollar industry on product portfolio needs and M&A considerations for multiple $5MM+ NPV projects. He also advised C-level executives for their medical device regulatory and business strategy needs. Gilly has been instrumental in the regulatory testing, documentation, and filing aspects of 13 Class II, 1 IDE, and 1 IND FDA medical device products. Gilly has over 25 peer reviewed published articles in the orthopaedic medical device field. Gilly holds 13 published or granted patents in the field of big-data driven surgery, additive manufacturing for medical devices, and robotic surgery, and presented foundational research at various peer-reviewed conferences and publications. Gilly holds a Bachelor of Science in Industrial Engineering from NJIT, a Master of Science in Biomedical Engineering and an MBA from Columbia University.

Elissa Ross

Elissa Ross is a mathematician and the CEO of Toronto-based startup Metafold 3D. Metafold makes an engineering design platform for additive manufacturing, with an emphasis on supporting engineers using metamaterials, lattices and microstructures at industrial scales. Elissa holds a PhD in discrete geometry (2011), and worked as an industrial geometry consultant for the 8 years prior to cofounding Metafold. Metafold is the result of observations made in the consulting context about the challenges and opportunities of 3D printing.


Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Fundraising, Venture Capitalists, Angel Investors in Healthcare 3D Printing (Premium)

One of the most exciting missions at 3DHEALS is discovering early-stage startups, meeting the founders, and helping these companies with fundraising through our Pitch3D program. Our goal is to save the founders and selected institutional investors time to meet each other at the right time along the company’s journey at zero cost to either side. Since April 20th, 2018, 3DHEALS has hosted numerous online and offline Pitch3D sessions regularly, introducing 30+ startups from all over the world to institutional investors who are interested in healthcare 3D printing, bioprinting, and adjacent fields including AI and cybersecurity (within 3D printing), 3D scanning, VR/AR, 3D Visualization, synthetic materials, and regenerative medicine. In this unique 3DHEALS virtual event, we would like you to meet some of the VCs and angel investors behind the scene and learn more about the medical device and biotechnology investment environment under the current macroeconomy. The format of this event will focus on a moderated panel discussion focusing on the current status, short-term, and longer-term outlook of the institutional investment landscape. The audience is welcome to bring many questions to this rare and unique opportunity and engage live.


Tak Cheung

Tak joined NEA in 2018 and is currently a Partner on the healthcare team. He focuses on medical device investments.

Prior to NEA, Tak was a Venture Partner at Merieux Development Venture Fund where he led all phases of investment for healthcare startups, including sourcing, diligence and investment approvals. Tak also co-founded Lexington Medical, a commercial-stage medical device startup in the gastrointestinal surgery space. Prior to Merieux and Lexington, Tak was VP of Business Development for the Global Surgical Division at Bausch & Lomb, and was responsible for all business development efforts in the ophthalmic surgical division. Tak has held various corporate and business development leadership roles at Edwards Lifesciences in the Heart Valve Therapy Division and Advanced Medical Optics (acquired by Johnson & Johnson).

Tak received a BS with Honors in Engineering and Applied Science from the California Institute of Technology, an MD from the University of California, Irvine, and an MBA from Harvard Business School.

Tom Gwinn

Tom Gwinn is an Investment Manager at Evonik Venture Capital (EVC) based in Silicon Valley. Tom has been actively involved in the technology community in the valley for over a decade. Prior to joining Evonik, Tom has held roles in venture capital investing, startup patent strategy, and applied physics research — providing a broad set of experiences to draw upon in support of Evonik’s investments. Tom has a B.S. in Electrical Engineering from Caltech, an M.S. in Electrical Engineering from Stanford, and a J.D. from Stanford Law School.

Tom Vogelsong

Tom is an angel investor in MedTech and a Life Science Advisor to and Director of Deal Flow for Kyto Technology and Life Science ( Tom is also an advisor to Medtech Innovator, Silicon Valley Advantage, US Angels, Edge AI and Embedded Vision Alliance, Camdo, InQCel, and Lehigh University’s new College of Health. He received his PhD in Electrical Engineering and has a background in technology, entrepreneurship, medical devices, and biochemistry. Tom scouts early-stage investment opportunities for Kyto in MedTech, BioTech, Diagnostics, and Tech. He has executive experience along with technical expertise and business development background with startups, including as CEO of venture-backed Photon Vision Systems, as well as with medium and large size companies including GE Medical. Tom has invested in startups and helped companies raise capital as well as coaching them to set a vision for growth and making connections for them to achieve success. Tom invests in MedTech and Tech directly as an angel investor and as part of Kyto.

Natalie Levy

Natalie Levy is the Founder of She’s Independent, a women-first investment group offering an entirely new way to support women’s financial independence and influence through investing and board placements. As a member-led investment group, She’s Independent marries empowerment and action, with the ultimate mission of closing the power gap in investing by getting more women on the cap table, in the boardroom, and into positions of influence. Over the next 12 months, She’s Independent plans to deploy $1.5M of capital collectively, and has invested in 9 deals since its formation in January 2022. An accomplished engineer turned Wall Street derivatives trader, investor, and advisor, Natalie has over a decade of tech operational experience, a portfolio of 30+ seed through later stage private investments, and has experienced liquidity events across 3 of the first 4 investments in her growth technology portfolio with an average return >20X. Natalie resides in Boulder, CO with her loving rescue pup Beans and is passionate about gender equity and mental health awareness.

Jimmy Lu

Jimmy is a Co-Founder & Managing Director of Eos BioInnovation, a new venture that incubates projects and invests in early-stage startups in the Regenerative Medicine field originating from top academic and research institutions.  

Prior to Eos, Jimmy was a Managing Director/Senior Partner in the San Francisco office of WI Harper, bringing over 25+ years of technology/healthcare and venture capital experience. While at WI Harper, he had been the leader of the healthcare team investing in the medical device, healthcare services and biotech/life science sectors. Jimmy was a Board Director of DeepBiome Therapeutics, Panorama Medicine, Kindstar Globalgene Technology, China Diagnostics Medical Corporation (Chemclin), StemCyte Inc., and Circle Pharma.

Before joining WI Harper, Jimmy co-founded and was a General Partner of iD Ventures (Acer Technology Ventures), with key investments that included iRobot Corporation, Harmonix Music, Monolithic Power Systems, and Fortinet.

Jimmy earned a BA from Yale College, an MBA from Harvard Business School and a JD from UC Berkeley School of Law. He serves on the University of Florida College of Engineering West Coast Advisory Board, and he is a member of the advisory board of Elm Street Ventures and is Co-Chair of the Investment Committee for the National Foundation for Cancer Research AIM-HI Accelerator Fund (Women’s Venture Competition).

Arno Held

Arno Held is Managing Partner of AM Ventures and specializes on the firm‘s ecosystem, as well as its global footprint and organizational growth. He started AM Ventures together with Johann Oberhofer in 2014. In total, Arno has more than 23 years of experience in industrial laser and manufacturing technologies and spent more than half of this time in the world of industrial 3D printing. 

Since founding AM Ventures, Arno has been instrumental in building the AM Ventures team that has scouted more than 2,500 3D printing startups all over the world, conducted more than 35 rounds, built a €100m VC fund and today holds a portfolio of 17+ shareholdings in 6 countries on 3 continents. 

Arno holds a diploma degree in industrial engineering and management from the University of Applied Sciences Karlsruhe (Germany) as well as an international executive MBA from the University of St. Gallen (Switzerland). Arno completed his studies in Shanghai, China and Cape Town, South Africa.


Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

3D Printing Organ on a Chip, Microfluidics Devices (Premium) 

The latest advantages of utilizing 3D printing for the fabrication of microfluidic devices and organ-on-a-chip systems have opened up new horizons in biomedical research and personalized medicine. 3D printing offers precision and flexibility that traditional methods often cannot achieve, enabling the rapid and cost-effective production of intricate microscale structures that mimic the complexity of human organs and tissue environments. Researchers can now customize microfluidic devices to emulate specific physiological conditions, allowing for more accurate drug testing and disease modeling. Moreover, the ability to integrate multiple materials in a single print enables the recreation of tissue interfaces and vascular networks, fostering the development of more lifelike organ-on-a-chip platforms. This innovative approach promises to revolutionize drug development, toxicology testing, and disease understanding, offering a glimpse into a future where personalized medicine is driven by these advanced, 3D-printed microsystems. 


Elliot McAllister

Elliot McAllister is the Founder of Skyphos, the first 3D printing fabrication system enabling a shift from the enterprise of mold-based prototyping and production for healthcare-based needs. Mr. McAllister has experience and expertise in Materials Science, Mechanical Engineering, Optics and developing microfluidic platforms. He has an advanced degree from Virginia Tech where his research focused on micro-3D printing 4 different forms of solid matter. Based on additive manufacturing technology, Mr. McAllister launched Skyphos to eliminate the barriers to entry of new applications in medical diagnostics and focuses on micro-scale requirements of microfluidics (uF), Lab-on-a-Chip (LOAC), Point-of-Care (POC) devices, as well as the needs of the sensors community. Skyphos leverages robotics, specialized materials, and the innate flexibility of a Digital Manufacturing platform to enable start-ups to get to market sooner – and large companies to reduce costs associated with developing new ones.

Natan Barros

I am a dedicated researcher with a passion for academic and translational research. My journey began with a bachelor’s degree in chemistry, where I developed a keen interest in biochemistry and polymers. Pursuing advanced studies in biotechnology at Sao Paulo State University (UNESP), one of Brazil’s leading institutions, I delved into biomaterials science and tissue engineering during my master’s and Ph.D. There, I focused on developing functional biomaterials for drug delivery and chronic wound healing. In 2019, I embarked on a transformative experience as a visiting researcher at the University of California, Los Angeles (UCLA) under the guidance of Dr. Ali Khademhosseini. At UCLA, I pioneered a microfluidic in vitro platform to model skin and explored innovative areas such as 3D bioprinting of functional skeletal muscle tissues and localized melanoma treatment. My dedication to groundbreaking research continued at the Terasaki Institute for Biomedical Innovation (TIBI), where I collaborated with esteemed mentors like Dr. Khademhosseini and Dr. HanJun Kim. Together, we investigated cutting-edge projects funded by NIH, including drug-eluting biomaterials for chemoembolization and bioengineered solutions for enterocutaneous fistula healing. Now, as a faculty fellow, I lead my research group at TIBI, focusing on shear-thinning hydrogels, microfluidic droplet platforms, and 3D bioprinted in vitro tissues.

Soon Seng Ng

Dr. Soon Seng Ng is an accomplished biomedical scientist and Director of Biology at Systemic Bio, leading groundbreaking research in 3D bioprinting and MPS development. With prior roles at Sana Biotechnology, Imperial College London, and Stanford University, Dr. Ng has made significant contributions in liver stem cell biology, disease modeling, drug discovery, and liver cell therapy. He has over 20 peer-reviewed publications, and his work has garnered awards and multi-million dollars grants, highlighting his impact on translational medicine and his commitment to bringing new therapies to patients. Dr. Ng’s dedication to advancing biomedical research and improving patient outcomes establishes him as a highly influential figure in the field.

Anna Bickham

Anna Bickham is the cofounder and CEO of Acrea 3D. Anna received her Ph.D. in chemistry from Brigham Young University in Dr. Adam Woolley’s lab, focusing on traditional and 3D printed fabrication of various medical and electrical microfluidic devices. She then spun Acrea 3D out of the technology used during her doctoral program, originating out of Dr. Greg Nordin’s lab. Acrea 3D specializes in micro-scale DLP-SLA printing of void features down to 20 um. By leveraging mechanical, software, and physical techniques, Acrea 3D enables true microfluidic 3D printing.

Register (Free)


Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Point of Care 3D Printing (Premium)

Point of care 3D printing is becoming one of the biggest attractions in adopting 3D printing in healthcare systems because it demonstrates the ability to decentralize manufacturing personalized medical devices. The medical devices can range from anatomical modeling, and implants, to surgical guides based on the latest updates from all over the world. However, for companies interested in expanding markets either locally or regionally, understanding the complex relationships among different players and regulations are critical.

At the end of 2021, the FDA published its discussion paper on the subject, inviting the public to submit comments so that more clarifying regulatory guidance can be created.


Ido Bitan

Ido Bitan is a Product Manager in Stratasys’s Medical Solutions Department. Mr. Bitan received a Bachelor of Science in biomedical engineering from Beer Sheva University in Israel. Mr. Bitan began his career at a start-up company, where he worked as part of the Research & Development team to develop new cancer-detecting equipment that assists surgeons in the operating room. Mr. Bitan has helped establish Stratasys’s adaption to the medical industry, leading the development of the Digital Anatomy Printer, Digital Anatomy Creator, and many more of the accompanying materials and software features. The Medical Department at Stratasys continues to push the boundaries of technology to improve patient care worldwide, and Mr. Bitan is passionate about improving the healthcare system to ensure better outcomes for any patient.

Martin Herzmann

Martin Herzmann started his medtech career in 1999 at Brainlab Headquarter in Germany. After wworking positions in Sales, Product Management and Business Development, he joined Ziehm Imaging in 2007 and worked for another eight years as Marketing Director for medical capital equipment. In 2015, he joined the Materialise and transformed his past experiences into medical 3D printing. In 2019, Martin joined Kumovis as Business Development Manager. The company enables medical device companies and hospitals to manufacture 3D printed implants, instruments and guides following regulatory standards and norms. Kumovis has a clear focus on medical 3D printing with high-performance polymers and biodegradable polymers. With the merger of Kumovis and 3D Systems in April 2022 Martin now can focus even more on additive manufacturing at Point-of-Care and accelerates the global implementation of clinical applications such as cranial implants printed in PEEK.

Kerim Genc

Kerim Genc

Kerim Genc is the Business Development Manager for the Simpleware Product Group at Synopsys. He joined Simpleware in 2011 as a Technical Sales Consultant and is currently responsible for managing global sales, business development and partnerships. He received his BS and MS in biomechanics from the University of Calgary and the Pennsylvania State University respectively and completed his PhD in Biomedical Engineering at Case Western Reserve University looking at countermeasures to spaceflight induced bone loss and fracture risk.

Silvina Zabala-Travers

Silvina Zabala-Travers

– MD and Radiologist Degree from Universidad de la República (UdelaR) in Uruguay – 3D training at Sant Joan de Déu Hospital 3D Lab (Expert3D and internship) in Barcelona, Spain Dr Zabala-Travers introduced 3D technologies to the academic medical field in Uruguay in 2019 and has since pioneered its development with particular interest in training radiologists to be part of the workflow to ensure process precision. She founded and leads the Surgical Virtual Planning and 3D Printing Area at the Radiology Department Pereira Rossell Hospital Center, a state and university laboratory for the application of 3D technologies in diagnostics, surgical virtual planning, clinical simulation and education for pediatric and adult patients. She recently teamed-up with a custom-implant manufacturer to co-found UPGRADE Medicals, a healthcare 3D-technology start-up which provides anatomical biomodels, virtual planning with surgical guide design and custom implant in metal, PEEK and bioabsorbable materials. She is invited professor at the Expert3D course and has given many conferences sharing her experience implementing a hospital 3D lab in a low-resource facility, as well as hands-on training on segmentation, biomodeling and virtual planning for bioengineers and surgical specialists.  She presides the Latin American Society of Pediatric Radiology (SLARP) New Technologies Committee, a network for the implementation of 3D technologies in Latin American countries. She also works as Radiology Section Editor for the Elsevier Journal Annals of 3D Printed Medicine, currently Guest Editor for the Special Issue “Virtual Planning and Personalized Medicine”.


Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, founder/CEO of 3DHEALS. Her main interests include next generation education, 3D printing in the healthcare sector, automated biology, artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Biomaterials Bioinks for 3D Printing (Premium)

Biomaterial development plays a crucial role in advancing the 3D printing industry, particularly in the fields of healthcare, regenerative medicine, and tissue engineering. The ability to create complex, patient-specific structures using 3D printing and bioprinting opens up unprecedented possibilities for personalized medical treatments and advancements in healthcare. Biomaterials specifically designed for 3D printing (or Bioinks for Bioprinting) enable the fabrication of intricate, biocompatible structures with precise mechanical and biological properties. By tailoring biomaterial formulations to mimic the characteristics of native tissues, researchers and clinicians can create scaffolds, implants, and organ constructs that promote cell growth, tissue regeneration, and integration with the host body. Moreover, the continuous exploration and refinement of biomaterials for 3D printing contribute to the development of innovative medical devices, drug delivery systems, and surgical tools. As biomaterial development progresses, it drives the expansion of the 3D printing industry’s capabilities, offering new solutions for personalized healthcare and revolutionizing patient care and treatment outcomes. In this upcoming event, we invite a panel of experts to dive deep into the current status, immediate future, and long-term outlook on biomaterials/bioink for healthcare 3D printing applications.


Julien Barthes


Dr. Julien BARTHES, CEO and co-founder of 3Deus Dynamics holds an engineering degree in physical chemistry of polymers and a PhD in biomaterials science. He has a solid experience in tissue engineering and additive manufacturing He experienced project leading of different type of funding and domains, as PANBIORA-H2020 and IMMODGEL-FP7 (European projects on biomaterials/implants) or FASSIL (National FUI project on AM). During these projects he maturated a strong experience in the field of tissue engineering, with a deep focus on cell and biomaterials interaction, as well as in AM technologies. He was involved in both academic and industrial R&D projects with a constant implication in the scientific dissemination, with more than 25 articles published. Before starting 3Deus Dynamics in 2020, he was working for the past 6 years in a MedTech startup developing ENT medical devices and he managed the development of medical devices from the laboratory stage to their marketing.

Gurkaran Chowdhry

Gurkaran Chowdhry is a polymer physicist and a co-founder of 3D BioFibR Inc, a pioneering biotechnology company at the forefront of biomaterial innovation and manufacturing. As the Director of Business Development and Operations, he has raised $5 million in funding within three years, enabling the successful commercialization of five groundbreaking biomaterial products through direct sales and strategic partnerships. As an innovative leader, Gurkaran is determined to bring 3D BioFibR to the forefront of biomaterial fabrication and help move 3D bioprinting technologies towards clinical applications.

Rao S. Bezwada 

Rao Bezwada

An accomplished scientist and entrepreneur, Rao S. Bezwada, Ph.D. established Bezwada Biomedical, an innovation-based and technology-driven research company, in 2003. The company is focused on developing a wide range of novel absorbable polymeric biomaterials to enhance quality of life by producing next generation bioabsorbable medical devices with therapeutic applications. Dr. Bezwada earned a doctorate in chemistry from the Stevens Institute of Technology in New Jersey and has over 40 years of research experience in the medical device industry, including 20 years of service at Ethicon, Inc. (a Johnson & Johnson Company). While at Ethicon, Dr. Bezwada’s research and development efforts led to the launch of a number of products, including Monocryl®, a new ultra-pliable synthetic absorbable monofilament suture. This product has represented worldwide sales of more than two (2) billion dollars since its launch in 1993 and current annual sales of over 100 million dollars. In recognition of this invention, along with its development, Johnson & Johnson, Inc. awarded Dr. Bezwada the prestigious Johnson Medal in 1996. Dr. Bezwada has been a prolific inventor and has been issued more than 135 U.S. patents on absorbable polyurethanes, absorbable amino acid polymers, absorbable polyester amides, absorbable polyoxaesters, and controlled release polymers. FDA-approved products such as MONTAGE® Putty, MONTAGE Fast Set Putty, Montage Flowable Putty, and PERMATAGE Putty, marketed by Abyrx for wound healing and bone applications, are based on Bezwada Biomedical’s absorbable polyurethane technology. Dr. Bezwada has also pioneered specialty bio-inks for 3D printing applications. In addition to his passion for science and technical accomplishments, Dr. Bezwada has also established a non-profit organization, Society for Basic Needs, in India. This organization has a mission aimed at improving the quality of life for those less fortunate by providing them with essential amenities and opportunities for health and education.

Neeti Srivastava

Neeti Srivastava is the Director, R&D, Business Development and Quality Affairs at Bezwada Biomedical. Dr. Srivastava has 14 years of experience in development of absorbable polymers for medical devices, drug delivery and 3D Bioprinting. She made contributions for the development of absorbable polyurethane formulation that received 510K approval from the FDA and was commercialized as a bone hemostat by Abyrx, Inc. She led the quality efforts resulting in ISO 9001 certification of Bezwada Biomedical. Furthermore, Dr. Srivastava has authored several scholarly articles and has been published in international scientific journals, along with presentations at American Chemical Society and Society for Biomaterials conferences.

Nicole Black

Dr. Nicole Black is the Vice President of Biomaterials and Innovation for Desktop Health. Nicole grew up in Michigan before moving to Boston to attend Boston University as Trustee Scholar. There, she studied Biomedical Engineering with a minor in Mechanical Engineering and a concentration in Nanotechnology. Following graduation, Nicole worked briefly at a startup company developing drug-eluting implants for the treatment of epilepsy. In 2014, Nicole started her PhD work at Harvard University in the lab of Professor Jennifer Lewis. During graduate school, Nicole worked on interdisciplinary projects between the Wyss Institute for Biologically Inspired Engineering and Mass Eye and Ear hospital, alongside Dr. Aaron Remenschneider and Dr. Elliott Kozin. Specifically, she focused on developing biomimetic eardrum grafts using novel materials and 3D printing technologies. Nicole graduated with her PhD in 2020 and started a postdoctoral fellowship as a Gliklich Healthcare Innovation Scholar. During this time, Nicole co-founded Beacon Bio, a startup company developing 3D-printed regenerative tissue grafts. Beacon Bio was named the runner-up prize winner in the MassMEDIC IGNITE pitch competition and a $25k prize winner in the Harvard i-Lab President’s Innovation Challenge. As the CEO, Nicole led an early-stage acquisition of Beacon Bio to Desktop Metal in 2021. Nicole currently leads a team at Desktop Health, a healthcare division of Desktop Metal, to bring the PhonoGraft device for eardrum perforation repair to patients. She is also leading partnerships with other medtech companies to help them realize the potential of the 3D-Bioplotter for innovative medical devices. Nicole’s accolades include the Collegiate Inventors Competition Graduate Team Winner (2018), the Baxter Young Investigator Award (2020), the Lemelson-MIT Student Prize (2021), and Forbes 30 Under 30 in Manufacturing and Industry (2022). Nicole is passionate about inspiring the next generation of scientists and engineers, and she has led a variety of outreach and mentoring programs for K-12 and undergraduate students. In her free time, Nicole enjoys crafting, reading, kayaking, and spending time with her cat, Merlin.


Craig Rosenblum

Craig Rosenblum

Craig Rosenblum (TWITTER: @RosenblumCraig) is the Vice President & General Manager of Himed. Over 30 years of operation, Himed has become a global leader in calcium phosphate based biomaterial production and has developed proprietary plasma spray coatings and surface treatments. Craig and his team collaborate directly with dental and medical device manufacturers around the world to provide innovative biomaterial solutions. Craig discovered a unique application for MATRIX MCD® post-processing additively manufactured titanium implantable devices using Himed’s proprietary and biocompatible resorbable blast media. Himed has since formed a strategic partnership with Lithoz, a global market leader in 3D printing, to develop new bioceramic bioinks for medical 3D printing. Craig received his B.S. and M.S. degree in Materials Science & Engineering with a Biomaterials concentration from The Johns Hopkins University (Baltimore, MD). With a focus in biomaterials characterization, his groundbreaking research explored the variations in the microstructure and mechanical properties of dental enamel. These studies were the first to demonstrate the unique heterogeneous nature of enamel. Craig currently serves on The Johns Hopkins University Materials Science & Engineering Advisory Board.

Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, and founder/CEO of 3DHEALS. Her main interests include next-generation education, 3D printing in the healthcare sector, automated biology, and artificial intelligence. She is an angel investor who invests in Pitch3D companies.

Biomaterials for 3D Printing (Premium)

Biomaterial science is one of the major pillars of the successful advancement of 3D printed solutions for healthcare. In this webinar, we invited stakeholders from academia, industry, larger chemical and material companies, and rising startups to give you a comprehensive view of where material science technology for healthcare 3D printing is at. We aim to provide information with enough breadth and depth that is suitable for both the general public and industry experts.


Guillaume de Calan

Guillaume de Calan is founder and CEO of Nanoe, a leading supplier of high tech raw materials for the ceramic industry. Through our brand Zetamix, he also launched the first line of filaments for accessible 3D printing of ceramic and metal parts. At Nanoe, we believe material innovation is at the core of new emerging technologies such as 3D printing, Li Ion batteries, medical implants and many more, and we strive to develop and produce best in class raw materials for these applications.

Rao Bezwada


An accomplished scientist and entrepreneur, Rao S. Bezwada, Ph.D. established Bezwada Biomedical LLC, an innovation based and technology driven company. The company is focused on developing a wide range of novel absorbable polymeric biomaterials that represent platform technologies capable of enhancing the quality of life by producing next generation bioabsorbable medical devices with therapeutic applications. Dr. Bezwada is the inventor of numerous absorbable technologies including absorbable polyurethanes, absorbable amino acid polymers, absorbable polyester amides, absorbable polyoxaesters and controlled release polymers. Dr Bezwada’s absorbable polyurethane technology is used in FDA approved products, MONTAGE®, MONTAGE Fast Set Putty, Montage Flowable Putty and PERMATAGE Putty which has been commercialized by Abyrx corporation. In addition, our absorbable polymers are used as bioinks, adhesion prevention barriers, absorbable drug eluting stent coatings, tissue adhesives and sealants, medical device coatings, drug delivery polymers, drug device combinations, absorbable implantable devices and tissue engineering biomaterial scaffolds. Bioinks innovation is one of our specialties. We offer a portfolio of bioinks that consists of PEG Acrylates, PEG Methacrylate’s, PEG Acrylamides, functionalized PEGs and copolymers of PEG with PLGA and Caprolactone. These bioinks can be customized to meet the needs to the customers including molecular weight, viscosity etc. If you’re looking for specialty polymers for 3D printing, please get in touch to discuss your application requirements.

Caroline Lauret 

Caroline Lauret joined Evonik in 2018 as a Senior Business Manager for Medical Devices. Caroline’s expertise lies in the field of medical device applications and she has been active in this market for more than 15 years. Caroline studied Biomedical Engineering at the Technical University Eindhoven, the Netherlands, and obtained her Master’s degree in Material Sciences. She has a strong background in global sales management, Medical Devices, Polymer Technology, and Materials Science.

Thiago Borges

Dr. Thiago Borges is manager for customer projects at Evonik’s biomaterials center in Birmingham, Alabama. He has 13 years of experience in the medical device industry and is responsible for managing customer projects, providing technical application support, and managing internal innovation projects for medical device solutions. Thiago joined Evonik in 2015 and was previously a project manager for RESOMER® Filament and other products where he coordinated the development of technical grade and GMP grades for this product. Prior to Evonik, he worked for eight years in the medical device industry holding different positions in R&D and operations, in particular working with stents and embolization devices. Thiago holds a bachelor’s degree in Chemistry from University of Sao Paulo, and a PhD in Polymer Science & Engineering from Case Western Reserve University in the U.S.

Ben Hartkopp

Ben Hartkopp is an inventor and co-inventor of a new kind of 3D printing system capable of jetting extremely viscous materials. The first application that this system addresses is printing photorealistic, full dentures in a single process with a far less post process than current systems on the market. He currently focuses on patent writing and strategy, test design, and research and development.


Dr. Jenny Chen

jenny chen

Dr. Jenny Chen is trained as a neuroradiologist, founder/CEO of 3DHEALS. Her main interests include next generation education, 3D printing in the healthcare sector, automated biology, artificial intelligence. She is an angel investor who invests in Pitch3D companies.

3DHEALS Los Angeles: Discovering Healthcare 3D Printing

Live recording of past event in Los Angeles, September 26th, 2018.

Live Event Agenda:

7:00-7:10 PM Dr.  Jenny Chen  (3DHEALS)
7:10-7:15  PM Q & A
7:15-7:25 PM Mr. Steven Morris (BIOLIFE4D)
7:25-7:30 PM Q &A
7:30-7: 40 PM Dr. Sanjay Sinha (UCLA)
7:40- 7:45 PM Q & A
7:45-7:55  PM Dr. Ali Khademhosseini (UCLA)
7:55-8:00 PM Q&A
8:00-8: 10 PM Dr. August de Oliveira
8:10-8:15 PM Q&A
8:15-8:45 PM Panel Q&A

Mr. Steven Morris 

BIOLIFE4D Founder and CEO Steven Morris possess more than 20 years of extensive experience in precision manufacturing, including 15 years serving as President of privately-held Inland Midwest Corporation (IMC) where he led the company’s transformation into a premier, state-of-the-art facility catering exclusively to the medical technologies industry. After several years of high profitability, Steven negotiated a successful exit strategy and sold the company in 2011.  After remaining on as President for over two years, he left and started BIOLIFE4D, an emerging biotech company working on the technology to bioengineer a human heart viable for transplantation using a patient’s own cells. His diverse and comprehensive knowledge of medical devices, processes optimization, and medical technologies will be extremely beneficial to the success of BIOLIFE4D.

Dr. Ali Khademhosseini

Levi Knight Chair. Professor of Bioengineering, Chemical Engineering, and Radiology at UCLA, Previously @Harvard and @MIT for 16 years, biomedical researcher, innovator, mentor, world traveler, educator, ACS Nano Assoc. Editor

Dr. Sanjay Sinha

Dr. Sanjay Sinha is an Interventional Pediatric Cardiologist and Assistant Professor of Pediatrics at UC Irvine and UCLA Mattel Children’s Hospital. He completed his medical school at the University of Arizona college of medicine and then moved to Los Angeles for his training. He completed his pediatric residency, pediatric cardiology fellowship, and extra interventional procedural training at UCLA Mattel Children’s hospital. His research interests are in transcatheter valve replacement in congenital heart disease. He has worked extensively in the area of 3D modeling for both surgical and interventional procedural planning and is currently the co-founder of the Congenital and Structural 3D Printing Program at UCLA.

Dr. August De Oliveira

Dr. August De Oliveira graduated in the top 10% of his class at the University of Washington School of Dentistry in 1997. After moving to Los Angeles from Seattle, Dr. de Oliveira did an optional additional year in a General Practice Residency at the VA Sepulveda where he learned advanced techniques in Endodontics (Root Canals), Dental Implants, and Restorative Dentistry. Dr. de Oliveira lectures weekly all over the nation on three subjects: CAD/CAM (same day crowns), CBCT (3D x-rays), and dental implants. On implants, he lectures from the basics of single-tooth implants to advanced Edentulous (no teeth) treatment. He has been published in many peer-reviewed journals and is widely recognized as a pioneer in CBCT Guided Surgery. Dr. de Oliveira has developed software for numerous dental companies and has authored two textbooks on dental implants.

Healthcare 3D Printing Ecosystem: India (Premium)

In this lightning round, we would like to connect experts from the Indian healthcare 3D printing ecosystem with 3DHEALS audiences around the world, highlighting their breakthroughs, and entrepreneurial lives, and opening new conversation channels on partnerships. We have curated a group of highly diverse and representative panelists from dental 3D printing, medical 3D printing, and bioprinting space. While it is impossible to really dive deep into the entrepreneurial culture and ecosystem of the community without actually physically being there, we aim to bring the most influential voices to the virtual event to give everyone a taste of what it is like to invest in, work for, and partner with Indian startups in the space.


Mahesh Kappanayil

Dr.Mahesh Kappanayil is a Professor of Pediatric Cardiology at Amrita Institute of Medical Sciences and Research Center, Kochi, Kerala, India. He is also the founder and lead of the 3D Printing, Virtual Reality and Innovation Laboratory at Amrita. As a pediatric cardiologist, he has been involved with various facets of the field including high-end transcatheter interventions, advanced cardiac imaging and clinical research. He helped establish India’s first dedicated cardiac MRI program for congenital heart diseases at Amrita. He has been involved in exploring the application of 3D+ technologies in Healthcare for well over a decade. In 2015-16 he helped establish the region’s first “Point-of-Care” medical 3D printing Lab at Amrita, and in 2020-21 expanded the scope of the lab to Extended Reality applications for medicine. These Labs today are hub of multi-disciplinary innovations in leveraging 3D+ technologies for healthcare applications. He believes that technology is a great equaliser, and cutting-edge technologies of 3D Printing and Extended Reality are set to revoutionalise medicine and healthcare in a big way, even in limited resource environments. Dr.Mahesh has won several national awards and recognitions for his work in this area, and has numerous expert lectures and publications to his credit.

Piyush Padmanabhan

Piyush’s journey into the world of Bioprinting began with his experience in the organ transplantation sector. Post his under graduation from Vellore Institute of Technology, Piyush began his career in the pharmaceutical sector at Biocon Limited and then at Roche Pharmaceuticals, where he worked closely with physicians and transplant coordinators in Kidney and Liver Transplants. The ever-widening gap in organs available for transplant and the need for these organs was very apparent to him. This led him to begin Next Big Innovation Labs® with Alok and Pooja, the other two co-founders of the company. In his role as the CEO and Co-Founder of Next Big Innovation Labs®, Piyush has led various deep technology projects in bioprinting and has also played a pivotal role in raising central and state government funding for the company. Some of the projects he has led are the following: the development of India’s first customized 3D Bioprinter, the development of unique temperature control fixtures for diverse bioprinting components and AI/ML integration into Trivima Bioprinting Systems. Piyush currently holds two technology patents and one process patent in the domain of bioprinting and considers himself to be an eternal student. His goal is to one day bridge the gap in the organ transplantation sector and believes in deep collaborations to achieve this goal.

Mahesh Dhoka 

I have done post my bachelors, taxation, and law along with business management. later joined family business where we are making high purity iron powders and flakes for food, pharma, aerospace and engineering industries exporting to about 30 countries across the world. started 3D Incredible in 2017 with an idea to bring this technology to the masses in India specially with respect to medical applications. so far we have done close to 1400 implants across more than 30 cities in India working and promoting 3d printing with close to 700 surgeons. with respect to engineering, we work with companies across various sectors right from prototyping to small batch production.

Yearla Srinivasa Rao

Yearla Srinivasa Rao is presently working as a chief operating officer of Medoja Health Private Limited, which is a healthcare company with a focus on 3D printing of patient-specific bespoke customized implants using novel biomaterials, and manufacturing of biomaterials from natural sources for medical 3D printing applications. Bone defects are filled with ceramic granules traditionally in many cases, without considering the shape fidelity to the defect or providing vascular supply. Medoja addressed this by using a ceramic composition which can be 3D printable to address shape fidelity and generate vascular supply to it. Yearla completed his Ph.D. from the University of Hyderabad and has overall 6+ years of post PhD industrial experience in nanomaterials and biomaterials based product development for agriculture, cosmetic, nutraceuticals, and pharmaceutical industries. He managed project activities from BIRAC and DBT during his tenure in the industry along with working in a multidisciplinary environment to manage sales, marketing, production, and business development, teams.

Dr. Jatin Kakrani

Co-Founder – 

Certified Dental Implant & Digital dentistry trainer 

DCI accredited speaker 

Gold Medalist Prosthodontist |


Firoza Kothari

Firoza Kothari, Co-Founder & CTO – Anatomiz3D Medtech Pvt. Ltd. – A B.Tech in Biotechnology Engineering and now Forbes 30 under 30 – Asia – Healthcare and Science, 2020, Firoza Kothari started her journey to provide patient-specific medical solutions and one day end the organ donation problem by creating live organs out of patients’ stem cells. With that aspiration, she gave birth to Anatomiz3D, a startup focusing on medical 3D printing. She, along with her team, was the first to execute soft tissue models in India through Paediatric Cardiology, partial amputee prosthetic hand, the first kidney tumor case in India, and the model for tongue cancer was the first in the world. Being a Co-founder and CTO of Anatomiz3D, she, along with her team, has successfully added 2000 plus case studies. Her multi-disciplinary expertise prevails in converting 2D DICOM CT/MRI/Echo Scans to 3D Printed anatomical replicas, medical devices, and allied products, using various combinations of Hardware and Software, across multiple medical specializations. Anatomiz3D has played a vital role in creating the market for 3D Printing in the Medical industry in India since 2015 and is a pioneer for the same, also being the first in India to enable Hospital-Industry partnerships for Point-of-Care Labs.